What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Cohort\_1:HMPL-453 150mg QD continuously in 21-day cycles; Cohort\_2, Cohort\_3 and Cohort\_4:HMPL-453 tartrate 300 mg QD orally (for 14 consecutive days \[Day 1 to 14\], followed by 7 days off \[Day 15 to 21\], 21 days as a treatment cycle)”In the company’s words, NCT04353375 on ClinicalTrials.gov
- Tested for
- Advanced Intrahepatic Cholangiocarcinoma, Solid Tumor, Adult
- Main trialPhase 2/3
- “The goal of this clinical trial is to evaluate in patients with advanced intrahepatic cholangiocarcinoma harboring FGFR2 fusion/rearrangement. The main questions it aims to answer are: To evaluate the objective response rate (ORR) of HMPL-453 tartrate in the treatment of patients with advanced intrahepatic cholangiocarcinoma (ICC) habouring fibroblast growth factor receptor (FGFR) 2 fusions/rearrangements after at least one line of systemic treatment failure or intolerance Participants will receive HMPL-453 tartrate 300 mg QD orally (for 14 consecutive days \[Days 1 to 14\] followed by 7…”In the company’s words, NCT04353375 on ClinicalTrials.gov
Other drugs for Solid Tumor, Adult
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up1
- 30 Jun 2028Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | 30 Jun 2028 | HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma | |
| Phase 1/2Completed | 17 Jul 2025 | A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors | |
| Phase 1Completed | 28 Aug 2023 | HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study | |
| Phase 1Completed | 14 Mar 2025 | Study on [14C]HMPL-453(FGFR Inhibitor) in Healthy Chinese Adult Male Subjects | |
| Phase 1Completed | 31 Dec 2025 | The Study on Effects of CYP3A and P-glycoprotein Inhibitor Itraconazole and CYP Enzyme Inducer Rifampin of HMPL-453 Tartrate Tablets |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026